Certain β-blockers, particularly nonselective β-blockers, may be associated with adverse effects on glucose metabolism and insulin sensitivity, potentially leading to an increased risk of developing or exacerbating diabetes (Tomiyama and Yamashina, 2014). Here, INS is linked to diabetes mellitus.